Benjamin Krämer

11.3k total citations · 1 hit paper
127 papers, 4.6k citations indexed

About

Benjamin Krämer is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Hepatology. According to data from OpenAlex, Benjamin Krämer has authored 127 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 38 papers in Physiology and 29 papers in Hepatology. Recurrent topics in Benjamin Krämer's work include Chronic Obstructive Pulmonary Disease (COPD) Research (49 papers), Asthma and respiratory diseases (35 papers) and Respiratory Support and Mechanisms (31 papers). Benjamin Krämer is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (49 papers), Asthma and respiratory diseases (35 papers) and Respiratory Support and Mechanisms (31 papers). Benjamin Krämer collaborates with scholars based in Germany, United States and United Kingdom. Benjamin Krämer's co-authors include Roger Owen, Ulrich Spengler, Jacob Nattermann, Hans Dieter Nischalke, Mark Higgins, Cheryl Lassen, Tilman Sauerbruch, Christian Körner, A Glässner and David Lawrence and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and The Journal of Immunology.

In The Last Decade

Benjamin Krämer

121 papers receiving 4.4k citations

Hit Papers

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia 2020 2026 2022 2024 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
    2020 798 citations Benjamin Krämer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Krämer Germany 36 1.9k 1.7k 811 788 786 127 4.6k
Nicole P. Juffermans Netherlands 47 1.7k 0.9× 546 0.3× 2.0k 2.5× 1.0k 1.3× 1.1k 1.4× 282 7.6k
Hidesaku Asakura Japan 40 888 0.5× 308 0.2× 1.5k 1.9× 419 0.5× 1.1k 1.4× 283 6.0k
Marco Contoli Italy 34 2.5k 1.3× 2.5k 1.5× 1.2k 1.5× 472 0.6× 1.4k 1.8× 131 5.1k
Marisa B. Marques United States 37 547 0.3× 663 0.4× 582 0.7× 352 0.4× 1.9k 2.4× 172 6.2k
Roberto Cangemi Italy 37 322 0.2× 511 0.3× 844 1.0× 547 0.7× 325 0.4× 114 3.6k
Y Levo Israel 29 411 0.2× 407 0.2× 586 0.7× 196 0.2× 782 1.0× 147 3.8k
Mario Pirisi Italy 39 500 0.3× 314 0.2× 2.8k 3.5× 406 0.5× 588 0.7× 308 6.1k
Sascha David Germany 40 674 0.4× 215 0.1× 1.1k 1.3× 681 0.9× 746 0.9× 153 4.6k
Jan Kristian Damås Norway 46 546 0.3× 575 0.3× 2.5k 3.1× 496 0.6× 2.2k 2.8× 196 7.5k
Johannes R. Hov Norway 36 547 0.3× 826 0.5× 1.2k 1.5× 513 0.7× 342 0.4× 118 4.2k

Countries citing papers authored by Benjamin Krämer

Since Specialization
Citations

This map shows the geographic impact of Benjamin Krämer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Krämer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Krämer more than expected).

Fields of papers citing papers by Benjamin Krämer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Krämer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Krämer. The network helps show where Benjamin Krämer may publish in the future.

Co-authorship network of co-authors of Benjamin Krämer

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Krämer. A scholar is included among the top collaborators of Benjamin Krämer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Krämer. Benjamin Krämer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Krämer, Benjamin, et al.. (2024). Profiling Cell Heterogeneity and Fructose Transporter Expression in the Rat Nephron by Integrating Single-Cell and Microdissected Tubule Segment Transcriptomes. International Journal of Molecular Sciences. 25(5). 3071–3071. 1 indexed citations
2.
Fischer, Janett, Hamish Innes, Stephan Buch, et al.. (2023). High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis. JHEP Reports. 5(4). 100684–100684. 5 indexed citations
3.
Raabe, Jan, Kim M Kaiser, Michael ToVinh, et al.. (2023). Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis. Hepatology. 78(3). 787–802. 9 indexed citations
4.
Nischalke, Hans Dieter, Janett Fischer, Madlen Matz‐Soja, et al.. (2021). A genetic variant in toll‐like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. Liver International. 41(9). 2139–2148. 9 indexed citations
5.
Krämer, Benjamin, et al.. (2019). The Effect of Vitamin-A Deficiency on Experimental Tuberculosis in the Guinea Pig and Rabbit1, 2. American Review of Tuberculosis.
6.
Langhans, Bettina, Hans Dieter Nischalke, Benjamin Krämer, et al.. (2019). Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunology Immunotherapy. 68(12). 2055–2066. 120 indexed citations
7.
Goeser, Felix, A Glässner, P Kokordelis, et al.. (2015). HIV mono-infection is associated with an impaired anti-HCV activity of NK cells. AIDS. 1–1. 6 indexed citations
8.
Lutz, Philipp, Benjamin Krämer, Dominik J. Kaczmarek, et al.. (2015). A variant in the nuclear dot protein 52kDa gene increases the risk for spontaneous bacterial peritonitis in patients with alcoholic liver cirrhosis. Digestive and Liver Disease. 48(1). 62–68. 9 indexed citations
9.
Lehbert, Nicola, Benjamin Krämer, Veronica Huber, et al.. (2014). Is a double 6-minute walk test (6MWT) required as part of the routine assessment of pulmonary rehabilitation (PR) in COPD patients?. European Respiratory Journal. 44(Suppl 58). P1293–P1293. 1 indexed citations
10.
To, Yasuo, Masaharu Kinoshita, Sang Haak Lee, et al.. (2012). Assessing efficacy of indacaterol in moderate and severe COPD patients: A 12-week study in an Asian population. Respiratory Medicine. 106(12). 1715–1721. 9 indexed citations
11.
Eisenhardt, Marianne, A Glässner, Benjamin Krämer, et al.. (2012). The CXCR3(+)CD56Bright Phenotype Characterizes a Distinct NK Cell Subset with Anti-Fibrotic Potential That Shows Dys-Regulated Activity in Hepatitis C. PLoS ONE. 7(7). e38846–e38846. 35 indexed citations
12.
O’Donnell, Denis E., Richard Casaburi, Walter Vincken, et al.. (2011). Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respiratory Medicine. 105(7). 1030–1036. 114 indexed citations
13.
Korn, Stephanie, Oliver Kornmann, Leonard Dunn, et al.. (2011). Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD. European Respiratory Journal. 38(Suppl 55). p860–p860. 2 indexed citations
14.
Dunn, Leonard, Roland Buhl, Cheryl Lassen, Michelle Henley, & Benjamin Krämer. (2010). Blinded 12-Week Comparison of Once-daily Indacaterol and Tiotropium in COPD. CHEST Journal. 138(4). 719A–719A. 7 indexed citations
15.
Donohue, James F., Charles Fogarty, Jan Lötvall, et al.. (2010). Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium. American Journal of Respiratory and Critical Care Medicine. 182(2). 155–162. 273 indexed citations
16.
Woessner, Ralph, et al.. (2010). Efficacy, Safety and Pharmacokinetics of Indacaterol in Caucasian and Japanese Patients with Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation. 31(4). 247–255. 13 indexed citations
17.
Magnussen, H, C. Verkindre, Damon Jack, et al.. (2010). Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respiratory Medicine. 104(12). 1869–1876. 23 indexed citations
18.
19.
20.
Segal, Allen T., Eli O. Meltzer, Richard F. Lockey, et al.. (2003). Once-Daily Cetirizine Is Safe and Effective for Children with Allergic Rhinitis with and without Intermittent Asthma. Pediatric Asthma Allergy & Immunology. 16(4). 265–274. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole P. Juffermans Breakdown of academic impact, for papers by Hidesaku Asakura Breakdown of academic impact, for papers by Marco Contoli Breakdown of academic impact, for papers by Marisa B. Marques Breakdown of academic impact, for papers by Roberto Cangemi Breakdown of academic impact, for papers by Y Levo Breakdown of academic impact, for papers by Mario Pirisi Breakdown of academic impact, for papers by Sascha David Breakdown of academic impact, for papers by Jan Kristian Damås Breakdown of academic impact, for papers by Johannes R. Hov
Rankless by CCL
2026